Endothelial IFI16 drives vasculopathy and profibrotic remodeling in systemic sclerosis by activating JAK/STAT signaling.
OBJECTIVE: Systemic sclerosis (SSc) is characterized by a prominent type I interferon (IFN-I) signature, yet the upstream drivers that link this signature to fibrosis remain unclear. This study aims to identify Interferon gamma-inducible protein 16 (IFI16) as an endothelial mediator that contributes to vasculopathy and fibrotic remodeling in SSc. METHODS: Machine-learning screening of public bulk RNA-seq was applied to identify fibrosis-associated IFN-I regulators. IFI16 expression pattern was validated by scRNA-seq, spatial transcriptomics and immunofluorescence. Functional and pathway analyses were performed in IFI16-overexpressing endothelial cells. RESULTS: A machine-learning-based analysis of bulk RNA-seq datasets demonstrated that IFI16 is significantly upregulated in SSc skin and ranks among the IFN-I-associated genes positively correlated with more severe skin fibrosis, shorter non-Raynaud disease duration, and elevated extracellular matrix deposition. Single-cell and spatial transcriptomic analyses revealed the enrichment of IFI16 in endothelial cells, and the co-localization of IFI16 with vasculature was validated by immunofluorescence. IFI16-high endothelial cells exhibited higher IFN activity and enhanced extracellular matrix remodeling. Stimulation with profibrotic or proinflammatory cytokines (IL-6, IL-1β, TGF-β and IFN-⍺) upregulated IFI16 expression in endothelial cells. Gain-of-function experiments showed that IFI16 overexpression impaired endothelial proliferation, migration, and tube formation, while driving the transition of endothelial cells towards mesenchymal cells through JAK-STAT signaling. Inhibition of JAK-STAT signaling reversed IFI16-induced endothelial-mesenchymal transition. CONCLUSION: Collectively, endothelial IFI16 coupled IFN-I signaling to vasculopathy and fibrotic remodeling via JAK-STAT activation, highlighting IFI16 as a promising therapeutic target in SSc vasculopathy and the subsequent fibrosis.
Authors
- Hejian Zou (ORCID: https://orcid.org/0000-0001-9762-2663)
- Lingbiao Wang (ORCID: https://orcid.org/0009-0000-4178-4858)
- Wenjing Ye (ORCID: https://orcid.org/0000-0003-0754-0643)
- Yiyun Yu (ORCID: https://orcid.org/0000-0002-6033-661X)
- Tim Filla (ORCID: https://orcid.org/0000-0001-5628-8398)
- Fangfang Chen (ORCID: https://orcid.org/0000-0001-9097-5036)
- Linlin Huang
- Weiguo Wan (ORCID: https://orcid.org/0000-0003-1095-8354)
- Jiucun Wang (ORCID: https://orcid.org/0000-0003-2765-0620)
- Xiaoxia Zhu
- Xue Yang
- Chen Chen
- Yi-Nan Li
- Yu Xue
- Ling Cao
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University (CN)
- Düsseldorf University Hospital (DE)
- Zhongshan Hospital (CN)
- Huashan Hospital (CN)
- Union Hospital (CN)
- State Key Laboratory of Genetic Engineering (CN)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1093/rheumatology/keag626
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00